

1    Supplementary Figures & Tables

2    Supplementary Figure 1: Percentage of array probes passing QC. Individual samples were  
3    evaluated for overall performance. Shown is the percentage of probes with Detected CpG  $p \leq$   
4    0.01 (high probe performance), data extracted from the Sample Table within GenomeStudio.  
5    Samples with low performance ( $> 2.5$  SD below the mean), shown below the horizontal line,  
6    were removed. The table at right of each graph shows the descriptive statistics of the sample set.

7    Supplementary Figure 2: Marker Selection Strategy. Recurrence-associated probes were  
8    identified using the Discovery Set of TNBC tumors (T) from patients who received loco-regional  
9    therapy only (IBCSG Test Set #1). Normal breast tissues (N = 5; NBr) served as controls.

10    Markers were filtered in a step-wise progression, as indicated.

11    The final marker set of 100 and a subset consisting of 30 markers identified based on the  
12    Discovery sample set only.

13    Supplementary Figure 3: Principal Component Analysis (PCA) was performed to visually  
14    inspect the methylation status of CpG loci probes among recurrent (blue ellipsoid) tumors versus  
15    non-recurrent tumors (brown ellipsoid). Each dot is an individual sample (Normal Breast  
16    samples, green, n = 5; tumor, red, n = 115) and represents the average methylation status across  
17    the CpG loci. A. 460,772/485,577 total CpG probes (detection p-value  $<0.01$ ). B. 59,581 cancer-  
18    specific probes (mean ratio Tumor/Normal samples  $\geq 1.5$ ), 12% of total CpG probes.

19    The scale for the axes is the same as in A). X- and Y- axes are re-scaling to enable closer visual  
20    inspection of the ellipsoids.

21    Supplementary Figure 4: Hypermethylation of 100 and 30 Marker Sets in Recurrent versus  
22    Non-recurrent Breast Cancers. The sum of beta array methylation for each 100 marker set and  
23    the 30 marker subset was calculated and displayed as box/whiskers plots (minimum to

24 maximum). For the test cohorts, the Mann-Whitney test was used to compare methylation levels  
25 among primary breast cancers that were Recurrent (R) versus Non-recurrent (NR).

26 Supplementary Figure 5: Cross-Platform Technical Validation of the Methylation Array.

27 Quantitative Multiplex Methylation Specific PCR (QM-MSP) was performed using a 9 CpG  
28 markers chosen from the 30 marker set according to their overall frequent hypermethylation in  
29 both the Discovery and IBCSG NoChemo Test arrays. Spearman Correlation shows strong  
30 correlation between array and QM-MSP methods.

31

32 Supplementary Table 1. 100 CpG Recurrence Markers Selected in the Discovery Cohort.

33 Supplementary Table 2. Chromosomal Localization of Methylated CpG Loci in the  
34 Combined Chemo Group. Logistic regression p-value is based on median methylation for each  
35 individual CpG locus of the 30 marker set in the combined IBCSG + Institutional Chemo cohort  
36 (26 cases and 95 controls). Correction for multiple testing was not performed.

37 Supplementary Table 3. Enrichment of CpG Loci Located on Chromosome 19.

38


Supplementary Figure 1.

**Discovery Strategy:  
Identification of Hypermethylated CpG Loci  
Associated with Recurrence**

485,577 CpG loci probes in total array, Discovery Set (N = 115)

- Selected subset of probes with best technical performance among individual control normal breast samples (Detection P ≤ 0.01; Selected 460,772 of 485,577 probes)
  - Selected probes hypermethylated in breast tumor but not normal breast (Tumor/Normal Breast MeanRatio ≥ 1.5; Selected 59,581 of 460,772 probes)
  - Selected probes hypermethylated selectively in recurrent primary tumors but not non-recurrent tumors (Recurrence/No recurrence MeanRatio; Selected 100 of 59,381 probes)
- ↓
- Identified 30 of 100 probes
    - Low background ( $\beta < 0.15$ ) in individual normal breast
    - Intensity  $\beta > 0.20$  in at least 4 of the 115 tumors


Supplementary Figure 2.




----- 2.5 SD threshold

Supplementary Figure 3.


a.



b.




Supplementary Figure 4.



Supplementary Figure 5.

Cross- Platform Validation of the Methylation Array –  
IBCSG No Chemo samples  
(12 recurrences; 30 controls)





Supplementary Table 2.

Table S2 Chromosomal Localization of Methylated CpG Loci and in the Combined Chemo Group\*

TargetID	SYMBOL	Log. Reg. P-Value	Chr. Band
cg17319787	ZNF699	0.0003	19p13.2
cg01703419	Not assigned	0.002	12q23.3
cg02196694	TOX	0.002	8q12.1
cg04541675	FAM71E1	0.002	19q13.33
cg09876101	WDR90	0.002	16p13.3
cg14942918	ONECUT3	0.002	19p13.3
cg20071051	NEK9	0.002	14q24.3
cg22286978	A1BG	0.002	19q13.43
cg26708638	ZNF444	0.002	19q13.43
cg11162249	NUDT16	0.008	3q22.1
cg13904493	MAP3K21	0.008	1q42.2
cg14237711	ZSCAN5A	0.008	19q13.43
cg24133836	AASS	0.008	7q31.32
cg01141940	RTN1	0.027	14q23.1
cg02837212	ETFB	0.077	19q13.41
cg14262439	TMEM132B	0.077	12q24.32
cg21877656	ZNF329	0.077	19q13.43
cg02666184	ETFB	0.187	19q13.41
cg08193650	ZFP36L2	0.187	2p21
cg12589600	GTF2F1	0.187	19p13.3
cg10594709	Not assigned	0.380	8q24.3
cg11070056	PRMT6	0.380	1p13.3
cg22884792	WNT1	0.380	12q13.12
cg18191418	Not assigned	0.661	3q21.3
cg19429286	ZNF699	0.661	19p13.2
cg19899312	Not assigned	0.661	11q13.5
cg01951637	CBFA2T3	1.000	16q24.3
cg08847533	NEK9	1.000	14q24.3
cg18892128	Not assigned	1.000	6p21.33
cg26029997	TREX1	1.000	3p21.31

\* Logistic regression p-value is based on median methylation for each individual CpG locus of the 30 marker set in the combined IBCSG + Institutional Chemo cohort (26 cases and 94 controls). Correction for multiple testing was not performed.

Supplementary Table 3.

Table S3 Enrichment of CpG Loci Located on Chromosome 19		
Marker Sets	# Situated on Chromosome 19	% (Enrichment)
Total array - 485577 loci	25521/485577	5.26 % probes specific for Ch. 19
100 locus recurrence marker set	15/100	15% (2.85 fold)
30 locus recurrence marker set	11/30	36.7% (6.98 fold)
14 loci of 30 marker set with significant association between recurrence and methylation *	6/14	42.9% (8.12 fold)

\* Determined by logistic regression, based on the median methylation level